Vanitha Ramakrishnan
About Vanitha Ramakrishnan
Vanitha Ramakrishnan is the Executive Director at BeiGene and Senior Director of CDx and Biomarker Development at BeiGene USA, with extensive expertise in Translational Medicine, Protein Chemistry, and Biomarkers.
Current Roles at BeiGene
Vanitha Ramakrishnan holds the position of Executive Director at BeiGene and Senior Director of CDx and Biomarker Development at BeiGene USA. In these roles, she focuses on advancing companion diagnostics and biomarker strategies to improve personalized medicine. Her work contributes to the development of precision therapies that can significantly impact patient outcomes in oncology.
Former Positions in Biotech Companies
Vanitha Ramakrishnan has a substantial history in the biotech industry, having worked in various senior roles throughout her career. She served as Vice President of PreClinical Research at Harpoon Therapeutics from 2015 to 2016 and was an Associate Director at Genentech for eight years from 2007 to 2015. Additionally, she worked as a Senior Director at PDL BioPharma from 2003 to 2007 and at Eos Biotechnology from 2000 to 2003. Her earlier roles included Senior Scientist positions at COR Therapeutics/Millenium SF from 1997 to 2000 and a post-doctoral fellowship at Genentech from 1986 to 1989.
Educational Background in Biochemistry
Vanitha Ramakrishnan completed her PhD in Biochemistry at The University of Kansas, where she studied from 1982 to 1986. Her educational background laid a strong foundation for her expertise in translational medicine, protein chemistry, and biomarker development. This academic experience has equipped her with the skills necessary to make significant contributions in the field of biotechnology.
Expertise in Translational Medicine and Biomarkers
Vanitha Ramakrishnan has extensive expertise in translational medicine, which aims to bridge the gap between laboratory research and patient care. She is skilled in the development and application of biomarkers—crucial tools for personalized medicine and targeted therapy. Additionally, her knowledge in protein chemistry aids in understanding and manipulating protein structures and functions, which are critical for developing therapeutic agents.
Experience in Antibody Development
Throughout her career, Vanitha Ramakrishnan has gained significant experience in antibody development. Antibodies are essential therapeutic agents used in treating various diseases, particularly in oncology. Her strong background in protein chemistry and biochemical research has enabled her to contribute to advancements in this area, further solidifying her position as a key player in the biotech industry.